The Dublin Zepatier Study
Open Label Study of the Safety and Efficacy of FDC Zepatier (Elbasvir+Grazoprevir +/- Ribavirin)Administered in a Community Based Setting to HCV Infected G1/4 Treatment naïve Patients on Stable Opiate Substitution Therapy With Cirrhotic and Non-cirrhotic Liver Disease
Sponsor: Mater Misericordiae University Hospital
Terminated
Insufficient study participants enrolled
Other terminated trials from Mater Misericordiae University Hospital
See all terminations from Mater Misericordiae University Hospital
Other Hepatitis C trials with similar outcome
A PHASE4 clinical study on Hepatitis C, this trial is terminated or withdrawn. The trial is conducted by Mater Misericordiae University Hospital and has accumulated 11 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE4
-
Jan 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
▶ Show 6 earlier versions
-
Aug 2018 — Jan 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
-
May 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mater Misericordiae University Hospital
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .